Black Rock Inc. Rallybio Corp Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Rallybio Corp stock. As of the latest transaction made, Black Rock Inc. holds 315,627 shares of RLYB stock, worth $299,845. This represents 0.0% of its overall portfolio holdings.

Number of Shares

315,627

Previous 1,675,966 81.17%

Holding current value

$299,845

Previous $3.1 Million 86.39%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.34 - $2.98 $1.82 Million - $4.05 Million	-1,360,339 Reduced 81.17%	315,627 $422,000
Q1 2024 May 10, 2024	SELL	$1.25 - $2.4 $99,535 - $191,107	-79,628 Reduced 4.54%	1,675,966 $3.1 Million
Q4 2023 Feb 13, 2024	BUY	$1.91 - $4.39 $237,420 - $545,694	124,304 Added 7.62%	1,755,594 $4.2 Million
Q3 2023 Nov 13, 2023	SELL	$3.37 - $6.16 $76,057 - $139,025	-22,569 Reduced 1.36%	1,631,290 $5.5 Million
Q2 2023 Aug 11, 2023	BUY	$4.31 - $8.89 $3.11 Million - $6.42 Million	722,364 Added 77.55%	1,653,859 $9.36 Million
Q1 2023 May 12, 2023	SELL	$4.37 - $8.75 $75,190 - $150,552	-17,206 Reduced 1.81%	931,495 $5.32 Million
Q4 2022 Feb 13, 2023	SELL	$4.67 - $14.86 $171,267 - $544,975	-36,674 Reduced 3.72%	948,701 $6.23 Million
Q3 2022 Nov 14, 2022	BUY	$7.54 - $14.56 $421,704 - $814,326	55,929 Added 6.02%	985,375 $14.3 Million
Q2 2022 Aug 12, 2022	BUY	$6.26 - $13.65 $133,225 - $290,499	21,282 Added 2.34%	929,446 $7.02 Million
Q1 2022 May 12, 2022	BUY	$6.91 - $15.04 $2.95 Million - $6.42 Million	426,656 Added 88.61%	908,164 $6.34 Million
Q4 2021 Feb 10, 2022	BUY	$9.3 - $19.91 $1.76 Million - $3.77 Million	189,304 Added 64.78%	481,508 $4.59 Million
Q3 2021 Nov 09, 2021	BUY	$10.83 - $23.4 $3.16 Million - $6.84 Million	292,204 New	292,204 $5.14 Million

Others Institutions Holding RLYB

# of Institutions

Shares Held

31.9M

Call Options Held

Put Options Held

View Full List

About Rallybio Corp

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $30.5M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

More about RLYB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account